Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,874Revenue $M75.3Net Margin (%)-69.4Altman Z-Score10.5
Enterprise Value $M2,795EPS $-0.6Operating Margin %-63.1Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-69.4Higher ROA y-yY
Price/Book73.710-y EBITDA Growth Rate %7.3Quick Ratio5.6Cash flow > EarningsY
Price/Sales33.55-y EBITDA Growth Rate %0.7Current Ratio5.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-32.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-118.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M127ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with HALO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HALOFirst Eagle Investment 2015-03-31 Reduce$9.82 - $16.2
($14.42)
$ 22.1053%Reduce 3.92%3,834,050
HALOFirst Eagle Investment 2014-09-30 Add0.02%$8.67 - $10.2
($9.52)
$ 22.10132%Add 30.25%3,640,480
HALOFirst Eagle Investment 2014-06-30 Add0.03%$7.09 - $12.31
($8.46)
$ 22.10161%Add 94.94%2,795,080
HALOKen Fisher 2014-06-30 Buy 0.02%$7.09 - $12.31
($8.46)
$ 22.10161%New holding791,760
HALOFirst Eagle Investment 2013-12-31 Buy 0.05%$9.66 - $15.7
($12.86)
$ 22.1072%New holding1,294,580
HALOGeorge Soros 2011-12-31 Sold Out -0.0018%$5.72 - $9.73
($8.21)
$ 22.10169%Sold Out0
HALOGeorge Soros 2011-09-30 Buy $5.62 - $7.29
($6.61)
$ 22.10234%New holding17,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HALO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kelley Kenneth JDirector 2015-06-18Sell20,000$215.24view
Kelley Kenneth JDirector 2015-03-05Sell40,000$15.3344.16view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.9148.31view
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.92147.76view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.96121.89view
Engler RobertDirector 2014-08-14Sell35,000$9.96121.89view
Engler RobertDirector 2014-05-15Sell126,700$7.56192.33view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.13142.06view
Shepard H. MichaelVP, Chief Scientific Officer 2013-08-19Sell10,000$7.11210.83view
FALBERG KATHRYN EDirector 2013-08-14Buy100,000$6.82224.05view

Quarterly/Annual Reports about HALO:

    News about HALO:

    Articles On GuruFocus.com
    buffet May 31 2015 
    buffet May 31 2015 
    Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
    comment on HALO May 12 2013 
    comment on HALO May 12 2013 
    comment on HALO May 12 2013 
    Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
    Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
    Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
    Halozyme Therapeutics Reports Second Quarter 2009 Financial Results Aug 07 2009 

    More From Other Websites
    VIDEO: 5 Minute Market Recap Jun 30 2015
    Lightning Round: Earnings on this are suspect Jun 25 2015
    Halozyme Therapeutics To Present At The JMP Securities 2015 Life Sciences Conference Jun 19 2015
    Halozyme Therapeutics To Present At The JMP Securities 2015 Life Sciences Conference Jun 19 2015
    5 Healthy Stocks in the Top Biotech ETF - ETF News And Commentary Jun 17 2015
    Can Halozyme Therapeutics (HALO) Run Higher on Strong Earnings Estimate Revisions? - Tale of the... Jun 11 2015
    6 stocks to watch Jun 10 2015
    Insiders and Hedge Funds Were Right About Halozyme Therapeutics, Inc. (HALO); Now They Are Buying... Jun 09 2015
    Holding(s) in Company Jun 09 2015
    HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 05 2015
    Halozyme Announces Plans For CFO Transition, Names Laurie Stelzer CFO Jun 05 2015
    Halozyme Announces Plans For CFO Transition, Names Laurie Stelzer CFO Jun 05 2015
    Halozyme-AbbVie Ink Deal for ENHANZE Platform, Shares Up - Analyst Blog Jun 04 2015
    Halozyme Stock Hits New High On AbbVie Collaboration Jun 03 2015
    How Halozyme Will Continue to Grow With Its New Deal Jun 03 2015
    Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie Jun 03 2015
    Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie Jun 03 2015
    Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free... May 31 2015
    Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free... May 31 2015
    Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For... May 27 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK